After opening the day in the red, share markets in India have traded on a volatile note and are presently trading below the dotted line. Sectoral indices are trading on a mixed note, with stocks in the capital goods sector and stocks in the realty sector witnessing maximum buying interest, while stocks in the banking sector are leading the losses.

The BSE Sensex is down up by 56 points (down 0.2%) and the NSE Nifty is trading down by 8 points (down 0.1%). Meanwhile, the BSE Mid Cap index is trading up by 0.2%, while the BSE Small Cap index is trading up by 0.3%. The rupee is trading at 64.90 to the US$.

In news from stocks in the pharma sector. Aurobindo share price is in focus today.

Aurobindo Pharma announced that it that it received final approval from the US Food and Drug Administration (USFDA), to manufacture Esomeprazole Magnesium capsules.

Esomeprazole Magnesium capsules are used in treatment of frequent heartburn, and are a generic version of AstraZeneca’s Nexium 24HR capsules. The company said that the product will be launched immediately.

The company added that the approved drug achieved annual sales of US$ 300 million.

This is the 127th Abbreviated New Drug Application (ANDA), including 23 tentative approvals, to be approved out of Unit VII formulation facility in Hyderabad, used for manufacturing oral products.

Aurobindo now has a total of 335 ANDA approvals (296 final approvals including 16 from Aurolife Pharma LLC and 39 tentative approvals) from USFDA

At the time of writing, Aurobindo Pharma share price was trading up by 0.6%.

The Indian pharmaceutical industry has come under a lot of regulatory pressure in the past few years.

The sector has faced great volatility over the years.

We had written about the current predicament of Indian pharma companies in one of the premium editions of the 5 Minute WrapUp: